Dialysate Sodium Individualization in Hemodialysis

• Status: Terminated
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentration leads to less thirst, interdialytic weight gain, and better BP control in hypertensive patients. In this study we will evaluate the mechanisms underlying this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker of volume status.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Satellite Research
• Treatments: Dialysis Solutions

Criteria

Inclusion Criteria:

• ESKD on hemodialysis

• Hypertension, defined as average pre-HD BP >150/85 mmHg or use of antihypertensive drugs

• Average pre-HD serum sodium <139 mmol/L

Exclusion Criteria:

• Intradialytic hypotension

• Atrial fibrillation or other chronic tachyarrhythmia (due to effects on measuring equipment)

• Uncontrolled hypertension (average pre-HD BP >200/105 mmHg)

• Uncontrolled diabetes mellitus (due to problems on interpretation of serum sodium values)

• Debilitating illness

• Inability to provide written informed consent